Objective To observe the influence of clopidogrel combined with proton pump inhibitor (PPI) on the postoperative complication of percutaneous coronary intervention.Methods The clinical data of 600 patients who were taking clopidogrel antiplatelet therapy were retrospectively analyzed.All patients were divided into observation group (with PPI,n =300) and control group (without PPI,n=300).In-stent restenosis (ISR) and the adverse event rates were compared between the two groups during the period of follow up.Results The incidence of gastrointestinal bleeding was less in observation group than in control group (6.7％ vs.13.7％,x2 =8.048,P＜0.01),but the incidences of ISR,target vessel revascularization (TVR) and non-fatal myocardial infarction were higher in observation group than in control group(x2 =6.426、5.511、4.718,all P＜0.05).Conclusions Clopidogrel combined with PPI treatment can significantly reduce the risk of gastrointestinal bleeding,but increase the incidences of major adverse cardiovascular events.We suggest that PPI should be used with caution for the patients who need longer-term PPI use.

The advantages of LabVIEW are becoming more and more distinct in instruments design.The ECG signals from MIT database are introduced using LabVIEW on software platform.They are treated with band stop,high pass,low pass filters in turn,and then heart rate is analyzed and calculated.Finally the amplitude and duration of QRS are recognized.

The technology of bone tissue engineering has got rid from autologous bone implant and allograft bone. With the development in recent 20 years,the basic pattern of tissue engineered bone has already been constructed,consisting of related molecules to bone regeneration,active cells for osteogenesis and scaffold materials. The related molecule to bone regeneration is the dominant factor to determine the bio-activity of tissue engineered bone,and also is the key researches in the field of bone tissue engineering. As the molecule bio-mechanism of bone regeneration has been elucidated and molecule bio-techniques have been combined with bone tissue engineering,many achievements regarding the related molecules to bone regeneration are observed in bone induction mechanism,vector,gene therapy technology and the combined use,which all improve the effect of tissue engineered bone on repairing the bone defects.

Recently,increasing evidence suggests that gingivitis and periodontitis may be one of the etiological factors for some adverse pregnancy outcomes such as preterm birth,preeclampsia,fetal growth restriction and lateral miscarriage.Although there are some conflicting findings and potential problems regarding uncontrolled underlying risk factors,most of the clinical studies indicate a positive correlation of gingivitis and periodontitis with those complications.This review discusses the relationship and its possible pathological mechanism in order to better prevent the development of adverse pregnancy outcomes.

Objective To study the reverse roles of reverse effect of tetramethylpyrazine on the resistance to adriamycin in human ovarian carcinoma cell line A2780/ADM.Methods The drug sensitivity of A2780/ADM cells was measured by MTT assay.The intracellular concentration of ADM was determined by fluorescent spectrophotometry.The changes of cell apoptosis percentage of A2780/ADM was demonstrated by flow cytometry.Results The IC50 value of TMP in A2780/ADM cell line was significantly decreased by the non-cytotoxic dose or low-cytotoxic dose of TMP.The resistance reversing effect comparing with the IC50 value of ADM cells was respectively 2.07 folds.The intracellular ADM concentration in A2780/ADM cells was significantly elevated by TMP at the same dose and the cell apoptosis percentage was significantly increased by TMP.The expression of P-gp was reduced significantly by TMP.Conclusion TMP could reverse the resistance of human ovarian carcinoma of A2780/ADM cell line to ADM,which may be related to the increased intracellular.

"Yongling"oral liquid composed of Cordyceps miliaris and Ganoderma lucidum was prepared by biochemical means. By comparing three different formulations,it was found that the optimum ratio between C. miliaris and G. lucidum was 7:3,which presented the entire active principles in proper proportion while retaining the original natural color and flavor.The preparation is a high protein,low fat,nontoxic oral liquid with diversified therapeutic actions and devoid of side effects

Thrombolytic therapy for ischemic stroke has received wide attention. Now the thrombolytic therapy mainly includes intervenous thrombolysis, intra-arterial thrombolysis, combination of intravenous and intra-arterial thrombolysis, and mechanical thrombolysis. The review mainly presents the recent progress in this field.

Aim To observe the effect of DL-buthionine s ulfoximine(DL-BSO) on the radiosensitivity of rat C 6 glioma cells under the a erobic and the hypoxic condition. Methods The source of radiati on was 60Co ?-rays. The rats C 6 glioma cells were treated by radia tion alone or DL-BSO+radiation under the aerobic and the hypoxic condition. Col ony forming assay was used to measure effects of DL-BSO on the radiosensitivity . Results Radiosensitive effect of DL-BSO was time-depedent u nder the aerobic condition. After treatment with 0.1 mmol?L -1 DL-BSO fo r 2, 6, 12 hours, the radiosensitive effect was not observed, whereas an enhance ment of radiosensitivity was seen at 24 and 48 hours. An enhancement of radiosen sitivity was seen at 2～48 hours after treatment with 0.1 mmol?L -1 DL-B SO under the hypoxic condition. The radiosensitive effects related to DL-BSO co ncentration under the aerobic and the hypoxic condition. Conclusion Both under the aerobic and the hypoxic conditions DL-BSO can increase the radio sensitivity of rat C 6 glioma cells. DL-BSO increased the rat C 6 gliom a cells radiosensitivity especially under the hypoxic condition, and radiosensit ive effect of DL-BSO is time and concentration-dependent.

BACKGROUND:The regional gene therapy of bone defect is to transfer genes capable of accelerating bone healing into target cells, which will transcript the genes into mRNA and translate them into proteins, then the target cells will be stimulated to differentiate under the role of protein, and finally reach the purpose of accelerating bone healing by means of autocrine or paracrine. With the development of cell recombination technique, more and more genes of growth factors involved in the bone repairing have been successfully cloned, which make it possible to treat bone defect with gene therapy. The present status for the regional gene therapy of bone defect is summarized.DATA SOURCES: An online search in Pubmed database was undertaken to identify articles about the regional gene therapy of bone defect published in English from January 1965 to January 2006 by using keywords of "gene therapy,bone defect". Meanwhile, Chinese relevant articles published from January 2000 to January 2006 were searched in Wanfang database by using the same keywords in Chinese.STUDY SELECTION: The data were primarily checked, and the references of each article were looked up. Inclusive criteria: related to the regional gene therapy of bone defect. Exclusive criteria: repetitive study or Meta analysis.DATA EXTRACTrON: Totally 237 articles were collected, 32 of them were in accordance with the inclusive criteria, and the other 205 were old or repetitive ones. Of the 32 articles, 4 were about the selection of destination genes, 3 about the selection of target cells, 7 about the selection of gene expression vector, 3 about the methods of gene transfer, 4 about gene therapy combined with tissue engineering in treating bone defect, 5 about polygenes in treating bone defects, and 2 about the problems and prospects in the gene therapy of bone defect.DATA SYNTHESIS: The regional gene therapy of bone defect is a new technique developed base on the basic theoretical cognition of bone regeneration and gene recombination technique, and provides ideal solving program for the treatment of bone defect caused by various reasons. The basic problems mainly include the selection of destination genes, selection of target cells, selection of gene expression vectors and the selection of the methods of gene transfer.The studies about the selection of target cells and methods of gene transfer become mature day by day, bone marrow stromal cells have become the target cells should be selected firstly, and it has been generally acknowledged that ex vivo gene transfer has more obvious advantages than in vivo one. The key problem at present is how to further explain the natural process of the repair of bone defect, and select the most effective component from the signal molecules involved in the process to apply in the gene therapy of bone defect, and further improve the gene expression vector, so as to ensure the safety of gene therapy. It is believed that with the continuously deepened theoretical cognition of bone regeneration and the continuous perfection of gene recombinant technique, the gene therapy of bone defect will finally go out of laboratory, and really serve the patients with bone defect.CONCLUSION: The regional gene therapy of bone defect can effectively activate the activity of bone regeneration at the site of bone defect, also can avoid the problems of immunologic rejection and systematic toxicity caused by the direct application of cytokines, and has good prospects of clinical application. At present, this technique is not completely perfect, and there are many problems to be deeply investigated in destination genes, gene vectors and transfection technique, etc.

Mitochondria are involved not only in energy metabolism but also in free radical metabolism. Superoxide anion can be generated through a way of electron leak of respiratory chain and the reactive oxygen species (ROS ) can be formed in the further reactions of O2* in mitochondria. The role of mitochondria in anti-oxidant functions and cell apoptosis is discu ssed in terms of electron leak of respiratory chain, uncoupling of oxidative pho sphorelation, mitochondrial pore, Box- or/and PTP-mediated release of cytochro me c from mitochondria and so on. The signaling act of ROS is emphasized in the regulation of cell apoptosis.